Thurston Springer Miller Herd & Titak Inc. Raises Holdings in Eli Lilly and Company $LLY

Key Points

• Thurston Springer Miller Herd & Titak increased its Eli Lilly stake by 43.8% in the second quarter, bringing its holdings to 4,965 shares valued at approximately $5.96 million. Institutional investors own 82.53% of Lilly’s stock.
• Lilly reported strong quarterly results, with EPS of $8.38 versus $6.40 expected and revenue of $22.97 billion, up 47.7% year over year. Growth was driven by demand for its diabetes and obesity medicines, and the company raised its 2026 outlook.
• The stock traded near its 52-week high at $1,186.71, while analysts maintained a generally bullish view with a “Moderate Buy” consensus and an average price target of $1,292.18. Lilly also declared a quarterly dividend of $1.73 per share, yielding about 0.6%.

Thurston Springer Miller Herd & Titak Inc. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 43.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,965 shares of the company's stock after acquiring an additional 1,512 shares during the period. Eli Lilly and Company accounts for approximately 2.2% of Thurston Springer Miller Herd & Titak Inc.'s investment portfolio, making the stock its 4th biggest holding. Thurston Springer Miller Herd & Titak Inc.'s holdings in Eli Lilly and Company were worth $5,957,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Osbon Capital Management LLC acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $25,000. Basso Capital Management L.P. bought a new stake in Eli Lilly and Company in the fourth quarter worth approximately $30,000. Maseco LLP lifted its stake in Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after buying an additional 28 shares during the period. E Fund Management Hong Kong Co. Ltd. lifted its stake in Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock valued at $32,000 after buying an additional 24 shares during the period. Finally, Aventus Investment Advisors Inc. boosted its holdings in shares of Eli Lilly and Company by 270.0% during the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company's stock worth $34,000 after buying an additional 27 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Down 0.4%

NYSE LLY opened at $1,186.71 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,249.45. The business has a 50 day moving average price of $1,159.38 and a 200-day moving average price of $1,047.55. The company has a market cap of $1.12 trillion, a price-to-earnings ratio of 39.82, a P/E/G ratio of 1.38 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company had revenue of $22.97 billion for the quarter, compared to analysts' expectations of $20.82 billion. During the same period last year, the business earned $6.31 EPS. Eli Lilly and Company's quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 37.55 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is 23.22%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Beat-and-raise quarter reinforces growth outlook. Lilly reported second-quarter revenue of approximately $22.97 billion and EPS of $8.38, exceeding consensus estimates. Revenue increased 47.7% year over year, and management raised 2026 revenue guidance to $85 billion-$87 billion from $82 billion-$85 billion, primarily because of strong demand for its diabetes and obesity medicines. Eli Lilly raises 2026 outlook again as Q2 soars past estimates
• Positive Sentiment: Weight-loss portfolio continues to drive investor enthusiasm. Mounjaro sales rose 91%, while Mounjaro and Zepbound together generated nearly $15 billion, widening Lilly’s lead over Novo Nordisk. Foundayo adoption is also gaining traction, Medicare access is expanding, and retatrutide is progressing toward a potential 2027 regulatory filing. LLY Q2 Earnings Call Raises Outlook as Foundayo Gains Traction
• Positive Sentiment: Analysts remain bullish. Truist raised its price target to $1,376 and maintained a Buy rating, while Cantor Fitzgerald lifted its target to $1,410 with an Overweight rating. Analysts cited durable incretin demand and the stronger long-term growth outlook. Eli Lilly’s Incretin Performance Supports Long-Term Growth
• Positive Sentiment: Favorable legal news removes a potential overhang. Lilly and Novo Nordisk defeated an antitrust lawsuit concerning the GLP-1 drug market, reducing near-term litigation risk. Lilly, Novo defeat antitrust lawsuit over GLP-1 drug market
• Neutral Sentiment: Retatrutide is being offered to some patients before FDA approval. Early access could generate real-world experience and strengthen demand, but the treatment remains subject to regulatory approval and related safety scrutiny. Eli Lilly offers new weight loss drug to some patients before FDA approval
• Negative Sentiment: Profit-taking and valuation concerns may be limiting the response. Following the earnings-driven advance, Lilly trades at roughly 40 times earnings and near its record high. Investors may be demanding continued execution, while expanding access through Amazon and competing obesity drugs could increase pricing and market-share pressure.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Weiss Ratings raised shares of Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a research report on Wednesday, July 1st. Wall Street Zen downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday, July 18th. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an "overweight" rating in a research note on Thursday. Leerink Partners raised their price target on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an "outperform" rating in a report on Thursday, June 25th. Finally, Jefferies Financial Group lifted their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a "buy" rating in a research note on Tuesday, June 9th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus target price of $1,292.18.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source